Back to Results

Basel Medical Group (BMGL)

Basel Medical Group Ltd is a Singapore-based healthcare provider listed on NASDAQ under the ticker BMGL. The company focuses on orthopedic care across general and subspecialized areas, including trauma and sports medicine, knee and hip replacement procedures, spine surgery, foot and ankle surgery, and minimally invasive orthopedic treatment. It also provides neurosurgical services, along with health screening, mental health, women’s health, and general practice services. Its operations further include medical consultations, diagnosis, and both medical and surgical treatment services. Incorporated in 2023, Basel Medical Group is headquartered in Singapore.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-BMGL
$7.28
30.0% Upside
Undervalued
—
—
—
Fair
—
—
—
0.0%
November 4, 2026
-1.1x
1.8x
0.8x
8.438 M
10.1 M
47.3%
32.0%
3.9
—
128.3%
Valuation • Fair Value

Basel Medical Group (NASDAQ-BMGL) Fair Value by Valuation Model

Compare the primary fair value estimate for Basel Medical Group (NASDAQ-BMGL) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$7.28

Estimated upside of 30.0% versus the current market price.

Fair Value Confidence

Very low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$7.28

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for Basel Medical Group (NASDAQ-BMGL) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Basel Medical Group (NASDAQ-BMGL)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

11.464 M

Current operating scale indicator.

Revenue Forecast

9.436 M

Forward revenue estimate.

EBITDA

-3.156 M

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review Basel Medical Group (NASDAQ-BMGL) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Basel Medical Group (NASDAQ-BMGL)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

2

Weak quality score that deserves closer review.

Beneish M-Score

-2.90

No elevated caution signal from this screen.

Altman Z-Score

3.9

Relatively strong balance-sheet zone.

FCF / Net Income

128.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Basel Medical Group (NASDAQ-BMGL). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Basel Medical Group (NASDAQ-BMGL)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

November 4, 2026

Days to Earnings

106

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Basel Medical Group (NASDAQ-BMGL), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Basel Medical Group (NASDAQ-BMGL) Stock Forecast & Technical Outlook

Review Basel Medical Group (NASDAQ-BMGL) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Buy

The 15-minute technical read for Basel Medical Group (NASDAQ-BMGL) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Basel Medical Group (NASDAQ-BMGL) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Basel Medical Group (NASDAQ-BMGL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Basel Medical Group (NASDAQ-BMGL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Basel Medical Group (NASDAQ-BMGL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Basel Medical Group (NASDAQ-BMGL)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for Basel Medical Group (NASDAQ-BMGL) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ • Fast Investor Answers

Basel Medical Group (NASDAQ-BMGL) Stock FAQ

Quick answers about Basel Medical Group (NASDAQ-BMGL) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$7.28
Estimated upside 30.0%
Valuation Rating
Undervalued
Estimated upside of 30.0%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Fair
Current financial-health read

The current fair value estimate for Basel Medical Group (NASDAQ-BMGL) is $7.28. This implies an estimated upside of 30.0% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 30.0% versus the current market price.

An analyst price target for Basel Medical Group (NASDAQ-BMGL) is not currently available in the latest data file.

The current financial health read for Basel Medical Group (NASDAQ-BMGL) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Basel Medical Group (NASDAQ-BMGL) is November 4, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Basel Medical Group (NASDAQ-BMGL) is -1.1x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Basel Medical Group is 8.438 M.

The current enterprise value listed for Basel Medical Group is 10.1 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Basel Medical Group is NASDAQ-BMGL, and the stock is listed on NASDAQ.

Basel Medical Group (NASDAQ-BMGL) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Basel Medical Group is 47.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Basel Medical Group is 32.0%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Providers & Services Stocks on NASDAQ View more

Guardant Health Inc (GH) Guardant Health Inc (GH)
Brightspring Health Services Inc (BTSG) Brightspring Health Services Inc (BTSG)
Brightspring Health Services Inc Unit (BTSGU) Brightspring Health Services Inc Unit (BTSGU)
The Ensign Group Inc (ENSG) The Ensign Group Inc (ENSG)
Henry Schein Inc (HSIC) Henry Schein Inc (HSIC)
Healthequity Inc (HQY) Healthequity Inc (HQY)
RadNet Inc (RDNT) RadNet Inc (RDNT)
Lifestance Health Group Inc (LFST) Lifestance Health Group Inc (LFST)
Alignment Healthcare LLC (ALHC) Alignment Healthcare LLC (ALHC)
Option Care Health Inc (OPCH) Option Care Health Inc (OPCH)
Privia Health Group Inc (PRVA) Privia Health Group Inc (PRVA)
Acadia Healthcare Company Inc (ACHC) Acadia Healthcare Company Inc (ACHC)
CorVel Corp (CRVL) CorVel Corp (CRVL)
Progyny Inc (PGNY) Progyny Inc (PGNY)
Clover Health Investments Corp (CLOV) Clover Health Investments Corp (CLOV)
Aveanna Healthcare Holdings Inc (AVAH) Aveanna Healthcare Holdings Inc (AVAH)
Surgery Partners Inc (SGRY) Surgery Partners Inc (SGRY)
Addus HomeCare Corporation (ADUS) Addus HomeCare Corporation (ADUS)
Astrana Health Inc (ASTH) Astrana Health Inc (ASTH)
NeoGenomics Inc (NEO) NeoGenomics Inc (NEO)
GeneDx Holdings Corp (WGS) GeneDx Holdings Corp (WGS)
InnovAge Holding Corp (INNV) InnovAge Holding Corp (INNV)
Adapthealth Corp (AHCO) Adapthealth Corp (AHCO)
Pennant Group Inc (PNTG) Pennant Group Inc (PNTG)